High bood pressure more likely to develop in people taking an integrase inhibitor and tenofovir alafenamide
Professor Francois Venter at IAS 2023. Photo by Roger Pebody/AidsmapThe development of high blood pressure (hypertension) after starting antiretroviral treatment in sub-Saharan Africa is common but can be managed with monitoring and low-cost generic drugs, Professor Francois Venter of the University of the Witwatersrand told the 12th International AIDS Society Conference on HIV Science (IAS 2023) in Brisbane, Australia.
“Mass HIV treatment programmes need to include support and funding for diagnosis and treatment for hypertension,” Professor Venter told the conference. In two large studies, between a third and half of participants had high or borderline high blood pressure after four years on treatment.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
Infectious Disease Special Edition: Immunomodulators in patients living with HIV
-
TheBodyPro: A new study on HIV, hypertension, and pregnancy is about a lot more than it seems
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.